Metrics as of 10/14/2026, 10:12 PM (Berlin time), refresh in progress.
Pacific Biosciences of California Stock
Pacific Biosciences of California, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Mark Van Oene
- Employees
- 485
- Market cap
- $618 M
- IPO
- 27/10/2010
- Web
- www.pacb.com
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing,…
Pacific Biosciences of California stock: price history
1D
-2.9%
1W
-26.8%
1M
+47.4%
6M
+24.4%
YTD
+6.4%
1Y
+25.2%
2Y
-2.9%
5Y
-91.8%
10Y
-76.7%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~34% stronger price swings than usual
Pacific Biosciences of California stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
2 more assignments (Enabler/Second row) Pro-only.
Pacific Biosciences specializes in the development and manufacturing of advanced platforms for genome sequencing and associated consumables. The business model combines the sale of proprietary sequencing systems with the continuous supply of essential biological reagents and specialized SMRT cells. These components are required to perform chemical sequencing reactions and generate significant recurring revenues through ongoing demand from the use of installed instruments. The customer base comprises a broad international spectrum, including research institutes, clinical laboratories, pharmaceutical companies, and agricultural organizations.
- Revenue model
- Mixed
- Recurring revenue
- High
- Pricing power
- Weak
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Low
Ask the agents about Pacific Biosciences of California
Analyst assessment of Pacific Biosciences of California
PRICE TARGET LOW
US$1.35
CONSENSUS
US$1.35
MEDIAN
US$1.35
PRICE TARGET HIGH
US$1.35
0
STRONG BUY
9
BUY
8
HOLD
1
SELL
0
STRONG SELL
18
TOTAL · Buy
As of: 11/05/2026
Pacific Biosciences of California stock metrics
P/E
-4.63
P/B
-18.61
EV/EBITDA
-11.58
RETURN ON EQUITY
134.7%
NET MARGIN
-114.7%
DEBT/EQUITY
-21.26
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.8%
FLOAT SHARES
303,830,571
AVG. DAILY VOLUME (30D)
14,803,168
Insider transactions (SEC)
Gibson James R II
Gibson James R II
Van Oene Mark
Van Oene Mark
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.9%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Pacific Biosciences of California stock
What does Pacific Biosciences of California do?
Pacific Biosciences of California, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Mark Van Oene, the company employs around 485 people.
The IPO was on 27/10/2010; the stock trades on NASDAQ under the ticker PACB.
What do analysts say about Pacific Biosciences of California stock?
18 analysts rate the stock, the consensus is Buy (as of 11/05/2026).
The average price target is US$1.35, ranging from US$1.35 to US$1.35, with a median of US$1.35.
This is an external assessment, not a statement by Market Jury.
When does Pacific Biosciences of California report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 34% stronger than usual.
Does Pacific Biosciences of California pay a dividend?
No, Pacific Biosciences of California currently does not pay a dividend.
Which stocks are comparable to Pacific Biosciences of California?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Pacific Biosciences of California stock analyzed?
Clicking "Analyze stock" lets five strategies assess Pacific Biosciences of California against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.